A study of aminoglutethemide and hydrocortisone in patients with advanced and refractory prostate carcinoma.
We have studied aminoglutethemide (AG) combined with hydrocortisone in 28 patients with advanced and refractory prostate carcinoma. All the patients had failed at least one endocrine therapy. Six patients received only one prior hormonal treatment. Five patients were off study within 3 weeks due to early death and toxicity, 14 had progressive disease, and 9 had stable disease. No objective partial remission was observed, but the nine stable patients had therapeutic benefit, with improvement in bone pain and performance status for a median duration of 153 days. Three patients withdrew because of postural hypotension, dizziness, weakness, and lethargy. The median survival of the entire group was 186 days (range 41-606 days). Our results suggest that aminoglutethemide and hydrocortisone can be an alternative treatment for patients with advanced and refractory prostate carcinoma.
Chang
A Y
AY
Department of Medicine, School of Medicine and Dentistry, University of Rochester, New York.
Bennett
J M
JM
Pandya
K J
KJ
Asbury
R
R
McCune
C
C
D000616:Aminoglutethimide / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D006854:Hydrocortisone / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009362:Neoplasm Metastasis; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D012074:Remission Induction; D013997:Time Factors
D000616:Aminoglutethimide; D006854:Hydrocortisone